Ticker: NUVB

Nuvation Bio Inc. (NYSE: NUVB) is currently navigating both opportunities and challenges that could significantly impact its future performance in the oncology market. Positive Aspects: Product Revenue Growth: In Q2 2025, the company reported product revenue of $1.2 million from U.S. sales of it...